# Filing Detail

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001213900-21-012577
Filing Date
2021-03-01
Accepted
2021-03-01 16:42:10
Documents
88
Period of Report
2020-12-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | ANNUAL REPORT | f10k2020_wizepharmainc.htm | 10-K | 1423783
2 | DESCRIPTION OF SECURITIES | f10k2020ex4-2_wizepharma.htm | EX-4.2 | 20230
3 | AMENDMENT TO EXCLUSIVE DISTRIBUTION AND LICENSING AGREEMENT BY AND BETWEEN WIZE | f10k2020ex10-40_wizepharma.htm | EX-10.40 | 26246
4 | SUBSIDIARIES OF THE COMPANY | f10k2020ex21-1_wizepharma.htm | EX-21.1 | 4221
5 | CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM | f10k2020ex23-1_wizepharma.htm | EX-23.1 | 4298
6 | CERTIFICATION | f10k2020ex31-1_wizepharma.htm | EX-31.1 | 9794
7 | CERTIFICATION | f10k2020ex31-2_wizepharma.htm | EX-31.2 | 9145
8 | CERTIFICATION | f10k2020ex32-1_wizepharma.htm | EX-32.1 | 5631
9 | CERTIFICATION | f10k2020ex32-2_wizepharma.htm | EX-32.2 | 5880
10 | GRAPHIC | image_001.jpg | GRAPHIC | 11822
| Complete submission text file | 0001213900-21-012577.txt |  | 6302208

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
11 | XBRL INSTANCE FILE | wizp-20201231.xml | EX-101.INS | 996852
12 | XBRL SCHEMA FILE | wizp-20201231.xsd | EX-101.SCH | 92758
13 | XBRL CALCULATION FILE | wizp-20201231_cal.xml | EX-101.CAL | 56066
14 | XBRL DEFINITION FILE | wizp-20201231_def.xml | EX-101.DEF | 232548
15 | XBRL LABEL FILE | wizp-20201231_lab.xml | EX-101.LAB | 481368
16 | XBRL PRESENTATION FILE | wizp-20201231_pre.xml | EX-101.PRE | 368061

Mailing Address 24 HANAGAR ST HOD HASHARON L3 4527713
Business Address 24 HANAGAR ST HOD HASHARON L3 4527713 972 472 260 0536
Wize Pharma, Inc. (Filer) CIK: 0001218683 (see all company filings)

EIN.: 880445167 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 000-52545 | Film No.: 21698607
SIC: 2834 Pharmaceutical Preparations